Portfolio company
Ability Biologics
Canada · £14.2m raised
Raised
£14.2m
Latest stage
Seed
Rounds recorded
1
Backed by
4 investors
Sectors
About
The company develops antibody biotherapeutics using artificial intelligence for patients with cancer, autoimmune and inflammatory diseases.
SourceFunding history · 1
Similar companies
Ability Biologics
The company develops AI-engineered antibody biotherapeutics targeting autoimmune diseases and cancer for patients with unmet medical needs.
ATB Therapeutics
The company develops engineered antibody therapies for patients with cancer and autoimmune diseases using a proprietary bioengineering platform.
Immunitas Therapeutics
This company develops antibody therapeutics for patients with cancer and autoimmune diseases.
Xaira
The company develops artificial intelligence platforms to design and develop antibody-based medicines for patients with various diseases.
Nabla Bio
This company develops generative artificial intelligence and high-throughput screening platforms to design therapeutic antibodies for pharmaceutical and biotechnology partners.
AbCellera Biologics
The company develops antibody-based medicines and discovery technologies for pharmaceutical and biotechnology partners to treat cancer, autoimmune disorders and infectious diseases.
Ditto Biosciences
The company develops parasite-derived protein therapies for pharmaceutical and biotechnology partners to treat patients with autoimmune diseases using an artificial intelligence platform.
Metaphore Biotechnologies
This biotechnology company develops an artificial intelligence platform to design functional antibody medicines for pharmaceutical partners and patients with autoimmune, metabolic or oncology conditions.